688062 Mabwell
- 25.31
- +0.91+3.73%
Mabwell News
Maiwei Biotech\'s announcement on changing some special accounts for fund-raising and re-signing the quadripartite supervision agreement
Haitong Securities Co., Ltd. inspection opinions on the matter of Miwei (Shanghai) Biotechnology Co., Ltd. changing some special accounts for fund-raising and re-signing the quadripartite supervisory agreement
Legal Opinion of Beijing Zhide (Shanghai) Law Firm on the 2024 Third Extraordinary General Meeting of Shareholders of Maiwei (Shanghai) Biotechnology Co., Ltd.
Announcement of Resolutions of the 2024 Third Extraordinary General Meeting of Shareholders of Maiwei Biotech
Notice of Maiwei Biotech on convening the 3rd Extraordinary General Meeting of Shareholders in 2024
Maiwei Biotech\'s 2024 “Improve Quality, Increase Efficiency, and Reward” Action Plan
Maiwei Biotech 2024 3rd Extraordinary General Meeting of Shareholders Meeting Information
Meiwei Biology voluntarily discloses the announcement of the Phase III clinical study of 9MW2821 combined with PD-1 monoclonal antibody for first-line treatment of urinary tract urothelial carcinoma, which has obtained the approval of the CDE.
Maiwei Bio voluntarily discloses the announcement regarding the Phase III clinical trial of 9MW2821 for the treatment of cervical cancer, which has obtained approval from the Center for Drug Evaluation (CDE).
Meiwei Biopharmaceutical voluntarily disclosed the announcement on the inclusion of 9MW2821 for the indication of urothelial carcinoma into breakthrough therapy drugs.
Announcement from Maiwei Biology regarding its wholly-owned subsidiary's signing of a licensing agreement with Runjia Pharmaceutical.
The verification opinion on the change of part of the fundraising special account and the re-signing of the four-party regulatory agreement by Maiwei (Shanghai) biotechnology Co., Ltd., submitted by Haitong Securities Co., Ltd.
Announcement on the change of the special account for raising funds and the re-signing of the quadrilateral supervision agreement by Maiwei Biology.
Announcement of resolutions from the second extraordinary shareholders' meeting of Maiwei Biotech in 2024.
Legal Opinion from Beijing Zhede (Shanghai) Law Firm regarding the 2024 Second Extraordinary General Meeting of Shareholders of Maui (Shanghai) Biotechnology Co., Ltd.
Announcement of Maiwei Biotech regarding the termination and re-provision of guarantees by the Company and its wholly-owned subsidiaries for wholly-owned subsidiaries
Notice of Maiwei Biotech on convening the 2nd Extraordinary General Meeting of Shareholders in 2024
Maiwei Biotech's announcement on the resignation of independent directors, nomination of independent directors, and adjustment of members of the 2nd Board of Directors Special Committee
Maiwei Biotech 2024 Second Extraordinary General Meeting of Shareholders Meeting Information
Maiwei Biotech voluntarily discloses an announcement on 9MW2821 to report clinical data and latest developments in the form of an oral report at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Analysis
Price Target
No Data
No Data